Novartis AG NOVN

SWX: NOVN | ISIN: CH0012005267   2/04/2026
123,20 CHF (+0,24%)
(+0,24%)   2/04/2026
Grafiek Novartis AG Grafiek Novartis AG

Novartis AG in het nieuws

29 maart 2026 · Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% · Persbericht

27 maart 2026 · Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation · Persbericht

23 maart 2026 · Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 · Persbericht

20 maart 2026 · Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline · Persbericht

13 maart 2026 · Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa · Persbericht

6 maart 2026 · Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting · Persbericht

27 februari 2026 · Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy · Persbericht

27 februari 2026 · Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) · Persbericht

25 februari 2026 · Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients · Persbericht

24 februari 2026 · New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer · Persbericht

Profiel Novartis AG

Farmaceutica
Gezondheidstechnologie
Medicinale en botanische productie
Productie

Mijn selecties